A comparative evaluation of properties and clinical efficacy of the echinocandins

Expert Opinion on Pharmacotherapy

Volumn 8, Issue 10, 2007, Pages 1479-1492

  Kim, Rose ^a   Khachikian, Deborah ^b   Reboli, Annette C ^a  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b DEPARTMENT OF VETERANS AFFAIRS   (United States)

Author keywords

Anidulafungin; Aspergillus; Candida; Caspofungin; Echinocandin; Invasive fungal infection; Micafungin

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; CARBAMAZEPINE; CASPOFUNGIN; CYCLOSPORIN A; CYTOCHROME P450; DEXAMETHASONE; ECHINOCANDIN; EFAVIRENZ; FLUCONAZOLE; ITRACONAZOLE; MICAFUNGIN; MYCOPHENOLIC ACID; NELFINAVIR; NEVIRAPINE; NIFEDIPINE; PHENYTOIN; POSACONAZOLE; PREDNISOLONE; PYRROLE DERIVATIVE; RAPAMYCIN; RIFAMPICIN; RITONAVIR; TACROLIMUS; VORICONAZOLE;

ABDOMINAL ABSCESS; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ANTIBIOTIC RESISTANCE; ANTIFUNGAL ACTIVITY; AREA UNDER THE CURVE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASPERGILLOSIS; ASPERGILLUS; BILIRUBIN BLOOD LEVEL; CANDIDA; CANDIDEMIA; CANDIDIASIS; CHILL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CREATININE BLOOD LEVEL; DIARRHEA; DOSE RESPONSE; DRUG ANTAGONISM; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG TISSUE LEVEL; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOCARDITIS; ESOPHAGUS CANDIDIASIS; FEBRILE NEUTROPENIA; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATITIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HYPOKALEMIA; IMMUNOCOMPROMISED PATIENT; INFECTION RISK; INFECTIOUS ARTHRITIS; LEUKOPENIA; LIVER DYSFUNCTION; LIVER FAILURE; LIVER FUNCTION TEST; LOADING DRUG DOSE; LOW DRUG DOSE; LUNG ASPERGILLOSIS; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MYCOSIS; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; OROPHARYNX CANDIDIASIS; OSTEOMYELITIS; PERITONITIS; PHARMACODYNAMICS; PHLEBITIS; PLEURISY; PRURITUS; REVIEW; SALVAGE THERAPY; SIDE EFFECT; SINGLE DRUG DOSE; THROMBOCYTOPENIA; VOMITING;

ANIMALS; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS; CANDIDA; CANDIDIASIS; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; GLUCOSYLTRANSFERASES; HUMANS; LIPOPROTEINS; MYCOSES; PEPTIDES, CYCLIC; TREATMENT OUTCOME;

EID: 34447515219     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.8.10.1479     Document Type: Review

References (83)

1. DENNING DW: Echinocandin antifungal drugs. Lancet (2003) 362:1142-1151.
2. MORRIS MI, VILLMANN M: Echinocandins; in the management of invasive fungal infections, part 1. Am. J. Health-Syst. Pharm. (2006) 63:1693-1703.
3. THEURETZBACHER U: Pharmacokinetics/pharmacodynamics of echinocandins. Eur. J. Clin. Microbiol. Infect. Dis. (2004) 23:805-812.
4. MERCK AND CO: Cancidas (caspofungin acetate for intravenous injection). Prescribing information (February 2005).
5. ASTELLAS PHARMA US: Mycamine (micafungin sodium for injection). Prescribing information (June 2006).
6. PFIZER INC.: Eraxis (anidulafungin for injection). Prescribing information (March 2006).
7. MCCORMACK PL, PERRY CM: Caspofungin. A review of its use in the treatment of fungal infections. Drugs (2005) 65:2049-2068.
8. MURDOCH D, PLOSKER GL: Anidulaftingin. Drugs (2004) 64:2249-2258.
9. LOUIE A, DEZIEL M, LIU W et al.: Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity. Antimicrob. Agents Chemother. (2005) 63:5058-5068.
10. ANDES D: Pharmacokinetics and pharmacodynamics of antifungals. Infect. Dis. Clin. North Am. (2006) 20:679-697.
11. WIEDERHOLD NP, KONTOYLANNIS DP, CHI J et al.: Pharmacodynamics of caspofungin in a routine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity. J. Infect. Dis. (2004) 190:1464-1471.
12. OSTROSKY-ZEICHNER. L, REX JH, PAPPAS PG et al.: Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob. Agents Chemother. (2003) 47:3149-3154.
13. ESPINEL-INGROFF A: In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazote posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature. Rev. Iberoam. Micol. (2003) 20:121-136.
14. ZAAS AK, ALEXANDER BD: Echinocandins: role in antifungal therapy, 2005. Expert Opin. Pharmacother. (2005) 6:1657-1688.
15. PFALLER MA, BOYKEN L, HOLLIS RJ et al.: In vitro susceptibilities of Candida spp. to caspofungin: four years of global surveillance. J. Clin. Microbiol. (2006) 44:760-763.
16. KROGH-MADSEN M, ARENDRUP MC, HESLET L et al.: Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient. Clin. Infect. Dis. (2006) 42:938-944.
17. LAVERDIERE M, LALONDE RG, BARIL JG et al.: Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis. J. Antimicrob. Chemother. (2006) 57:705-708.
18. PARK S, KELLY R, KAHN JN et al.: Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida spp. isolates. Antimicrob. Agents Chemother. (2005) 49:3264-3273.
19. STONE JA, MIGOYA EM, HICKEY L et al.: Potential for interactions between caspofungin and nelfinavir or rifampin. Antimicrob. Agents Chemother. (2004) 48:4306-4314.
20. HEBERT MF, BLOUGH DK, TOWNSEND RW et al.: Concomitant tacrolimus and micafugin pharmacokinetics in healthy volunteers. J. Clin. Pharmacol. (2005) 45:1018-1024.
21. HEBERT MF, TOWNSEND RW, AUSTIN S et al.: Concomitant cirlosporin and micafungin pharmacokinetics in healthy volunteers. J. Clin. Pharmacol. (2005) 45:954-960.
22. DOWELL JA, STOGNIEW M, KRAUSE D et al.: Assessment of the safety and pharmacokinetics of anidulafungin when administered with ciclosporin. J. Clin. Pharmacol. (2005) 45:227-233.
23. SANZ-RODRIGUEZ C, ARRANZ R, CISNEROS JM et al.: Absence of clinically relevant effect of caspofungin on cyclosporin pharmacokinetics. Swiss Med. Wkly. (2005) 135:658-659.
24. MARR KA, HACHEM R, PAPANICOLAOU G et al.: Retrospective study of the hepatic safety profile of patients concomitantly treated with caspofungin and cyclosporin A. Transpl. Infect. Dis. (2004) 6:110-116.
25. RUHNKE M: Comparison of micafungin and liposomal amphotericin B for invasive candidiasis. Abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (2005):M-722c.
26. VILLANUEVA A, ARATHOON EG, GOTTUZZO, E, BERMAN RS, DINUBILE MJ, SABLE CA: A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin. Infect. Dis. (2003) 33:1529-1535.
27. ARATHOON EG, GOTUZZO E, NORIEGA LM, BERMAN RS, DINUBILE MJ, SABLE CA: Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiasis. Antimicrob. Agents Chemother. (2002) 46:451-457.
28. VILLANUEVA A, GOTTUZZO E, ARATHOON EG et al.: A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am. J. Med. (2002) 113:294-299.
29. KARTSONIS N, DINUBILE MJ, BARTIZAL K, HICKS PS, RYAN D, SABLE CA- Efficacy of caspofungin in the treatment of esophageal candidiasis resistant to fluconazole. J. Acquir. Immune. Defic. Syndr. (2002) 31:183-187.
30. VEROUX M, MACARONE M, FLAMINGO P et al.: Caspofungin in the treatment of azole-refractory esophageal candidiasis in kidney transplant receipients. Transplant. Proc. (2006) 38:1037-1039.
31. PETTENGELL K, MYNHARDT J, KLUYTS T, LAU W, FACKLAM D, BUELL D: Successful treatment of oesophageal candidiasis by micafungin: a novel systemic antifungal agent. Aliment. Pharmacol Ther. (2004) 20:475-481.
32. DE WET N, LLANOS-CUENTAS A, SULEIMAN J et al.: A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients. Clin. Infect. Dis. (2004) 39:842-849.
33. DE WET NT, BESTER. AJ, VILJOEN JJ et al.: A randomized, double blind, comparative trial of micafungin (FK463) versus fluconazole for the treatment of oesophageal candidiasis. Aliment. Pharmacol. Ther. (2005) 21:899-907.
34. KOHNO S, MASAOKA T, YAMAGUCHI H et al.: A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycos is in Japan. Scand. J. Infect. Dis. (2004) 36:372-379.
35. ERNST EJ, ROLING EE, PETZOLD CR, KEELE DJ, KLEPSER ME: In vitro activity of micafungin (FK-463) against Candida spp.: microdilution, time-kill, and postantifungal-effect studies. Antimicrob. Agents Chemother. (2002) 46:3846.
36. BUELL D, KOVANDA L, DRAKE T, FISCO C: Alternative day dosing of micafungin in the treatment of esophageal candidiasis. Abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (2005):M-719.
37. KRAUSE DS, SIMJEE AE, VAN RENSBURG C et al.: A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin. Infect. Dis. (2004) 39:770-775.
38. KELLEY K, CHAPMAN S, CLEARY JD: Digestion of echinocandins. Abstracts of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (2005):M-366.
39. VASQUEZ J, SCHRANZ JA, KRAUSE D et al.: Efficacy of anidulafungin (ANID) in patients (Pts) with azole-refractory candidiasis (ARMC). Abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (2004):M-1038.
40. REX JH, WALSH TJ, ANAISSIE EJ: Fungal infections in iatrogenically compromised hosts. Adv. Intern. Med. (1998) 43:321-371.
41. WISPLINGHOFF H, BISCHOFF T, TALLENT SM, SEIFERT H, WENZEL RP, EDMOND MB: Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis. (2004) 39:309-317.
42. PFALLER MA, DIEKEMA DJ: Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida. Clin. Microbiol. Infect. (2004) 10(Suppl. 1): 11-23.
43. PAPPAS PG, REX JH, SOBEL JD et al.: Guidelines for treatment of candidiasis. Clin. Infect. Dis. (2004) 38:161-189.
44. MORA-DUARTE J, BETTS R, ROTSTEIN C et al.: Comparison of caspofungin and amphotericin B for invasive candidiasis. N. Engl. J. Med. (2002) 347:2020-2029.
45. REBOLI A, ROTSTEIN C, PAPPAS P et al.: Anidulafungin versus fluconazole for the treatment of candidemia and invasive candidiasis (C/ IC). Abstracts of the 45th Interscience Conftrence on Antimicrobial Agents and Chemotherapy. (2005):M-718.
46. KRAUSE DS, REINHARDT J, VAZQUEZ JA et al.: Phase II, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia. Antimicrob. Agents Chemother. (2004) 48:2021-2024.
47. OSTROSKY-ZEICHNER L, KONTOYIANNIS D, RAFFALLI J et al.: International open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia. Eur. J. Clin. Microbiol. Infect. Dis. (2005) 24:654-661.
48. STEVENS DA, MCCULLOUGH MJ, CLEMONS KV, MARTINEZ MC: Candida dubliniensis (Cd), a species with an extremely high frequenqr of paradoxical effect (PE) with caspofungin (CAS). Abstracts of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (2006):M-1756.
49. STEVENS DA, ICHINOMIYA M, KOSHI Y, HORIUCHI H: Escape of Candida from caspofungin inhibition at supra-MIC concentrations (paradoxical effect') accomplished by increased cell wall chitin; evidence for β-1,6-glucan synthesis inhibition by caspofungin. Abstracts of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (2006):M-363.
50. BETTS RF, ROTSTEIN C, TALWAR D et al.: Comparison of micafungin and caspofungin for candidemia or invasive candidiasis (IC). Abstracts of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (2006):M-1308a.
51. CORNELY O, LASSO M, BETTS R et al.: Prospective, multicenter study of caspofungin (CAS) for treatment (Rx) of less common forms of invasive candidiasis (IC). Abstracts of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (2006):M-893.
52. VAN BURIK JA, RATANATHARATHORN V, STEPAN DE et al.: Micafungin versus fluconazole for prophylaxis against fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin. Infect. Dis. (2004) 39:1407-1416.
53. MATTIUZZI GN, ALVARADO G, GILES FJ et al.: Open-labeled, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic mailignancies. Antimicrob. Agents Chemother. (2006) 50:143-147.
54. FORTUN J, MUNOZ P, MARTIN-DAVILA P et al.: Prospective, multicenter study of caspofungin (CAS) for prophylaxis in high risk liver transplantation (IT). Abstracts of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (2006):K-272.
55. WALSH TJ, TEPPLER H, DONOWITZ GR et al.: Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N. Engl. J. Med. (2004) 351:1391-1402.
56. MARR KA, CARTER RA, CRIPPA F, WALD A, COREY L: Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin. Infect. Dis. (2002) 34:909-917.
57. MORGAN J, WANNEMUEHLER KA, MARR KA et al.: Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program. Med. Mycol. (2005) 43(Suppl. 1):S49-S58.
58. LIN SJ, SCHRANZ J, TEUTSCH SM: Aspergillosis case-fatality rate: systematic review of the literature. Clin. Infect. Dis. (2001) 32:358-366.
59. KARTSONIS NA, SAAH AJ, LIPKA CJ, TAYLOR AF, SABLE CA: Salvage therapy with caspofungin for invasive aspergillosis: results from the caspofungin compassionate use study. J. Infect. (2005) 50:196-205.
60. MAERTENS J, RAAD I, PETRIKKOS G et al.: Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin. Infect. Dis. (2004) 39:1563-1571.
61. GLASMACHER A, CORNELY OA, ORLOPP K et al.: Caspofungin treatment in severely ill, immunocompromised patients: a case-documentation study of 118 patients. J. Antimicrob. Chemother. (2006) 57:127-134.
62. BETTS R, GLASMACHER A, MAERTENS J et al.: Efficacy of caspofungin against invasive Candida or invasive Aspergillus infections in neutropenic patients. Cancer (2005) 106:466-473.
63. CANDONI A, MESTRONI R, DAMLkNI D et al.: Caspofungin as first line therapy of pulmonary invasive fungal infections in 32 immunocompromised patients with hematologic malignancies. Eur. J. Haematol. (2005) 75:227-233.
64. JAFRI H, ZAOUTIS T, KELLER N et al.: Prospective, multicenter study of caspofungin (CAS) for treatment (Rx) of documented fungal infections in pediatric patients (Ped Pts). Abstracts of the 46th Imerscience Conference on Antimicrobial Agents and Chemotherapy (2006):G-873a.
65. DENNING DW, MARR KA, LAU WM et al.: Micafungin (FK463), alone or in combination with other systemic antifungal agents, for treatment of acute invasive aspergillosis. J. Infect. (2006) 53:337-349.
66. ARIKAN S, LOZANO-CHIU M, PAETZNICK V, REX JH: In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrob. Agents Chemother. (2002) 46:245-247.
67. PEREA S, GONZALEZ G, FOTHERGILL AW, KIRKPATRICK WR, RINALDI MG, PATTERSON TF: In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp. Antimicrob. Agents Chemother. (2002) 46:3039-3041.
68. SHALIT I, SHADKCHAN Y, SAMRA Z, OSHEROV N: In vitro synergy of caspofungin and itraconazole against Aspergillus spp.: MIC versus minimal effective concentration end points. Antimicrob. Agents Chemother. (2003) 47:1416-1418.
69. MANAVATHU EK, ALANGADEN GJ, CHANDRASEKAR PH: Differential activity of triazoles in two-combinations with the echinocandin caspofangin against Aspergillus fumigatus. J. Antimicrob. Chemother. (2003) 51:1423-1425.
70. SIONOV E, MENDLOVIC S, SEGAL E: Efficacy of amphotericin B or amphocericin B-intralipid in combination with caspofungin against experimental aspergillosis. J. Infect. (2006) 53:131-139.
71. MACCALLUM DM, WHYTE JA, ODDS FC: Efficacy of caspofungin and voriconazole combinations in experimental aspergillosis. Antimicrob. Agents Chemother. (2005) 49:3697-3701.
72. LUQUE JC, CLEMONS KV, STEVENS DA: Efficacy of micafungin alone or in combination against systemic murine aspergillosis. Antimicrob. Agents Chemother. (2003) 47:1452-1455.
73. GRAYBILL JR, BOCANEGRA R, GONZALEZ GM, NAJVAR LK: Combination antifungal therapy of murine aspergillosis: liposomal amphotericin B and micafungin. J. Antimicrob. Chemother. (2003) 52:656-662.
74. PETRAITIS V, PETRATIENE R, HOPE W et al.: Combination therapy of voriconazole and anidulafungin improves outcome of experimental pulmonary aspergillosis. Abstracts of the 46th Interscience Confrence on Antimicrobial Agents and Chemotherapy (2006):M-882.
75. ALIFF TB, MASLAK PG, JURCIC JG et al.: Refractory aspergillus pneumonia in patients with acute leukemia. Cancer (2003) 97:1025-1032.
76. KONTOYIANNIS DP, HACHEM R, LEWIS RE et al.: Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patientswith hematologic malignancies. Cancer (2003) 98:292-299.
77. MARR KA, BOECKH M, CARTER RA, KIM HW, COREY L: Combination antifungal therapy for invasive aspergillosis. Clin. Infect. Dis. (2004) 39:797-902.
78. SINGH N, LIMAYE AP, FORREST G et al.: Combination of voriconazole and caspofungin as primary therapy of invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation (2006) 81:320-326.
79. KONTOYIANNIS DP, RATANATHARATHORN V. VAN BURIK J et al.: Micafungin (MCF) alone or in combination with other licensed antifungal agent (OLAT) in bone marrow transplant (BMT) recipients with invasive aspergillosis (IA). Abstracts of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (2006):M-878.
80. FLYNN PM, SEIBEL N, ARRIETA A et al.: Treatment of invasive aspergiflosis (IA) in pediatric patients (Pts) with micafungin (MICA) alone or in combination with other systemic antifungal agents. Abstracts of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (2006):M-891.
81. REX JH, BENNETT JE, SUGAR AM et al.: A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N. Engl. J. Med. (1994) 331:1325-1330.
82. REX JH, PAPPAS PG, KARCHMER AW et al.: A randomized and blinded multicenter trial of high dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in non-neutropenic patients. Clin. Infect. Dis. (2003) 36:1221-1228.
83. KULLBERG BJ, SOBEL JD, RUHNKE M et al.: Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomized non-inferiority trial. Lancet (2005) 366:1435-1442.